1062599-72-7

Basic information

• Product Name: (5-fluoro-2-((2-(hydroxymethyl)-4-nitrophenyl)thio)phenyl)methanol
• Synonyms: (5-fluoro-2-((2-(hydroxymethyl)-4-nitrophenyl)thio)phenyl)methanol
• CAS NO: 1062599-72-7
• Molecular Weight: 309.318
• Mol File: 1062599-72-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (5-fluoro-2-((2-(hydroxymethyl)-4-nitrophenyl)thio)phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (5-fluoro-2-((2-(hydroxymethyl)-4-nitrophenyl)thio)phenyl)methanol(1062599-72-7)
• EPA Substance Registry System: (5-fluoro-2-((2-(hydroxymethyl)-4-nitrophenyl)thio)phenyl)methanol(1062599-72-7)

Safety Data

• Hazardous Substances Data: 1062599-72-7(Hazardous Substances Data)

Upstream product

• 120121-07-5 5-fluoro-2-mercapto-benzoic acid 
• 1062599-16-9 2-((2-carboxy-4-fluorophenyl)thio)-5-nitrobenzoic acid 
• 1062599-40-9 methyl 5-fluoro-2-(2-(methoxycarbonyl)-4-nitrophenylthio)benzoate 

Relevant articles and documents

DMT1 Inhibitors Kill Cancer Stem Cells by Blocking Lysosomal Iron Translocation

Cancer stem cells (CSC) constitute a cell subpopulation in solid tumors that is responsible for resistance to conventional chemotherapy, metastasis and cancer relapse. The natural product Salinomycin can selectively target this cell niche by directly interacting with lysosomal iron, taking advantage of upregulated iron homeostasis in CSC. Here, inhibitors of the divalent metal transporter 1 (DMT1) have been identified that selectively target CSC by blocking lysosomal iron translocation. This leads to lysosomal iron accumulation, production of reactive oxygen species and cell death with features of ferroptosis. DMT1 inhibitors selectively target CSC in primary cancer cells and circulating tumor cells, demonstrating the physiological relevance of this strategy. Taken together, this opens up opportunities to tackle unmet needs in anti-cancer therapy.

BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS

This invention is directed to compounds of formula (I): wherein m, n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.